Dr. Lynda Chin
The University of Texas MD Anderson Cancer Center
Department of Genomic Medicine
Our research program focuses on the molecular biology and genomics / epigenomics of cancer genesis, maintenance and progression in multiple tumor types, with an emphasis on glioblastoma and melanoma. Next-generation sequencing technologies are utilized to characterize mouse and human cancer genomes. We develop systematic approaches to integrate data across species (e.g. comparison of mouse and human tumors) and across platforms (e.g. DNA copy number, mutations, methylation and RNA expression) to identify candidate genes of interest. Conditional transgenic and knockout technologies are used to engineer cancer-relevant mutations in the mouse with the goal of generating cancer-prone conditions that recapitulate aspects of the human disease, particularly melanoma. One of our major areas of emphasis is the functional genomics study of metastasis. Our efforts are directed at (1) elucidating early genetic lesions in primary tumors that can drive the processes of metastatic progression and can thus be prognostic of future metastasis risks; (2) identifying progression drivers that are keys to enabling dissemination to distal organ sites, and (3) investigating the molecular mechanisms mediating melanoma metastasis. Leveraging genomic technology, computational network modeling and genetically engineered mouse models, we emphasize a system biology approach to understand complex signaling / pathways in metastasis and therapeutic responses/resistance. Ultimately, our goal is to rapidly functionalize such findings for translation into the clinic.
Office: MDA 4SCRB (Unit 91)
M.D. - Albert Einstein College of Medicine - 1993